Successful Use of Adalimumab for Treating Pyoderma Gangrenosum with Ulcerative Colitis under Corticosteroid-tapering Conditions
-
- Sagami Shintaro
- Department of Medicine and Molecular Science, Hiroshima University, Japan
-
- Ueno Yoshitaka
- Department of Endoscopy, Hiroshima University, Japan
-
- Tanaka Shinji
- Department of Endoscopy, Hiroshima University, Japan
-
- Nagai Kenta
- Department of Medicine and Molecular Science, Hiroshima University, Japan
-
- Hayashi Ryohei
- Department of Medicine and Molecular Science, Hiroshima University, Japan
-
- Chayama Kazuaki
- Department of Medicine and Molecular Science, Hiroshima University, Japan
この論文をさがす
抄録
A 52-year-old woman with ulcerative colitis was admitted to our hospital for an ulcerative colitis flare-up under salazosulfapyridine therapy. The symptoms improved with high-dose corticosteroids. After prednisolone was tapered to 10 mg, the frequency of diarrhea increased. The diarrhea was accompanied by joint pain and a skin ulcer with abscess formation, which was diagnosed to be pyoderma gangrenosum. The patient was started on adalimumab. A positive response to the adalimumab therapy was observed after 2 weeks, during which time the ulcerative skin lesion healed completely, however, colonic mucosal healing was achieved at 2 months. Therefore, adalimumab appears to be an effective therapeutic option for patients with ulcerative colitis-associated pyoderma gangrenosum.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 54 (17), 2167-2172, 2015
一般社団法人 日本内科学会